Ascorbic acid in charcot-marie-tooth disease type 1A (CMTTRIAAL and CMT-TRAUK): A double-blind randomised trial

The Lancet Neurology

Volumn 10, Issue 4, 2011, Pages 320-328

  Pareyson, Davide ^a   Reilly, Mary M ^b   Schenone, Angelo ^c   Fabrizi, Gian Maria ^d,f   Cavallaro, Tiziana ^d,f   Manganelli, Lucio ^e   Vita, Giuseppe ^g   Quattrone, Aldo ^h   Padua, Luca ^i,j   Gemignani, Franco ^k   Visioli, Francesco ^l,m   Laura M ^l   Radice, Davide ⁿ   Calabrese, Daniela ^a   Hughes, Richard A C ^b   Solari, Alessandra ^a   Salsano, C ^a   Nanetti, L ^a   Marelli, C ^a   Scaioli, V ^a,q   Ciano, C ^a   Rimoldi, M ^a,q   Lauria, G ^a,q   Rizzetto, E ^a   Camozzi, F ^a   Narciso, E ^c   Grandis, M ^c   Monti Bragadin, M ^c   Nobbio, L ^c   Casano, A ^d   Bertolasi, L ^d   Cabrini, I ^d   Corra K ^d   Rizzuto, N ^d   Pisciotta, C ^e   Nolano, M ^e,o   Mazzeo, A ^e   Aguennouz, M ^f   Di Leo, R ^f   Majorana, G ^f   Lanzano, N ^f   Valenti, F ^f   Valentino, P ^g   Nistico R ^g   Pirritano, D ^g   Lucisano, A ^g   Canino, M ^g   Pazzaglia, C ⁱ   Granata, G ⁱ   Foschini, M ⁱ   Brindani, F ^k   Vitetta, F ^k   Allegri, I ^k   Bogani, P ^l   Blake, J ^b   Koltzenburg, M ^b   Hutton, E ^b   Lunn, M ^b   Cavaletti, G ^p   Galimberti, S ^p   Santoro, L ^q   Manganelli, F ^q   Sereda, M ^q   more..

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

^g UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^h CNR   (Italy)

ⁱ CATHOLIC UNIVERSITY   (Italy)

^j IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^k UNIVERSITY OF PARMA   (Italy)

^l UNIVERSITY OF MILAN   (Italy)

^m IMDEA FOOD INSTITUTE   (Spain)

ⁿ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^o IRCCS   (Italy)

^p UNIVERSITY OF MILANO BICOCCA   (Italy)

^q UNIVERSITY OF GÖTTINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; PLACEBO;

ABDOMINAL CRAMP; ADULT; AGED; ANEMIA; ARTICLE; BRONCHITIS; CHARCOT MARIE TOOTH DISEASE TYPE 1A; CHOLELITHIASIS; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMORRHOID; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; INTERVERTEBRAL DISK HERNIA; ITALY; KIDNEY COLIC; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MULTICENTER STUDY; MUSCLE ISOMETRIC CONTRACTION; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SCORING SYSTEM; STOMACH PAIN; TELEPHONE; UNITED KINGDOM; VAGINAL CYST; VISUAL ANALOG SCALE; WALKING;

EID: 79952736703     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70025-4     Document Type: Article

References (24)

1. Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol 2009; 8: 654-67.
2. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004; 10: 396-401.
3. Kaya F, Belin S, Bourgeois P, MicaleffJ, Blin O, Fontés M. Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord 2007; 17: 248-53.
4. Verhamme C, de Haan RJ, Vermeulen M, Baas F, de Visser M, van Schaik IN. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med 2009; 7: 70.
5. Burns J, Ouvrier RA, Yiu EM, et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009; 8: 537-44.
6. Micallef J, Attarian S, Dubourg O, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2009; 8: 1103-10.
7. Reilly MM, de Jonghe P, Pareyson D. 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A). 8-10 April 2005, Naarden, The Netherlands. Neuromuscul Disord 2006; 16: 396-402.
8. Shy M. Ascorbic acid for treatment of CMT1A: the jury is still out. Lancet Neurol 2009; 8: 505-07.
9. Pareyson D, Solari A. Charcot-Marie-Tooth disease type 1A: Is ascorbic acid effective? Lancet Neurol 2009; 8: 1075-77.
10. Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005; 64: 1209-14.
11. Shy ME, Chen L, Swan ER, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008; 70: 378-83.
12. Pareyson D, Schenone A, Fabrizi GM, et al, for the CMT-TRIAAL Group. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27]. Pharmacol Res 2006; 54: 436-41.
13. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996; 93: 3704-09.
14. Institute of Medicine. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington, DC: National Academic Press, 2000.
15. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
16. Apolone G, Mosconi P. The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 1998; 51: 1025-36.
17. Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain 1983; 16: 87-101.
18. Solari A, Laurà M, Salsano E, Radice D, Pareyson D, on behalf of the CMT-TRIAAL Study Group. Reliability of clinical outcome measures in Charcot-Marie-Tooth disease. Neuromuscul Disord 2008; 18: 19-26.
19. Graham RC, Hughes RA. Modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry 2006; 77: 973-76.
20. Badrakhan C-D, Petrat F, Holzhauser M, et al. The methanol method for the quantification of ascorbic acid and dehydrosacorbic acid in biological samples. J Biochem Biophys Methods 2004; 58: 207-18.
21. Reilly MM, Shy ME, Muntoni F, Pareyson D. 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul Disord 2010; 20: 839-46.
22. Verhamme C, van Schaik IN, Koelman JH, de Haan RJ, de Visser M. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain 2009; 132: 3252-62.
23. Toth C. Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients. Acta Neurol Scand 2009; 120: 134-38.
24. Li J, Bai Y, Ghandour K, et al. Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain 2005; 128: 1168-77.